Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins.
Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 5 institutions in 1 country.
Evgeniia N BykoniaFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0002-2269-1469
Denis A KleymenovFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0001-9422-7238
Vladimir A GushchinFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0002-9397-3762
Andrei E SiniavinFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0001-7576-2059
Elena P MazuninaFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0003-0701-5152
Sofia R KozlovaFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0009-0009-6196-8262
Anastasia N ZolotarFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.
Evgeny V UsachevFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.
Nadezhda A KuznetsovaFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0002-7399-7628
Elena V ShidlovskayaFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.
Andrei A PochtovyiFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0003-1107-9351
Daria D KustovaFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0002-8382-275X
Igor A IvanovFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0001-6785-4420
Sergey E DmitrievFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.ORCID 0000-0002-1774-8475
Roman A IvanovTranslational Medicine Research Center, Sirius University of Science and Technology, Sochi 354340, Russia.ORCID 0000-0002-9573-4183
Denis Y LogunovFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.
Alexander L GintsburgFederal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow 123098, Russia.
Ministry of Health of the Russian Federation · RUSechenov University · RUInstitute of Bioorganic Chemistry · RULomonosov Moscow State University · RUSirius University of Science and Technology · RU
Funding
Ministry of Health of the Russian Federation 121102500071-6
6 · The paper itself
Abstract
SARS-CoV-2 variants have evolved over time in recent years, demonstrating immune evasion of vaccine-induced neutralizing antibodies directed against the original S protein. Updated S-targeted vaccines provide a high level of protection against circulating variants of SARS-CoV-2, but this protection declines over time due to ongoing virus evolution. To achieve a broader protection, novel vaccine candidates involving additional antigens with low mutation rates are currently needed. Based on our recently studied mRNA lipid nanoparticle (mRNA-LNP) platform, we have generated mRNA-LNP encoding SARS-CoV-2 structural proteins M, N, S from different virus variants and studied their immunogenicity separately or in combination in vivo. As a result, all mRNA-LNP vaccine compositions encoding the S and N proteins induced excellent titers of RBD- and N-specific binding antibodies. The T cell responses were mainly specific CD4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins. · full record | OpenQuestion